ArticleAnnals of medicine and surgery (2012)2026
Neuroprotective effects of glycine against cisplatin-induced cognitive decline in mice.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin is a common chemotherapeutic agent known to cause impairments often referred to as "chemo-brain." Preclinical evidence suggests cisplatin induces toxicity via oxidative stress and neuroinflammation. Methods: Twenty-five healthy adult male BALB/c mice ( Results: Cisplatin administration alone resulted in significant cognitive decline in the Y-naze ( Conclusion: Glycine co-administration largely prevents spatial learning and working memory deficits caused by cisplatin in mice. These findings support the view that cisplatin impairs cognition through inflammatory and oxidative pathways, and suggest that targeting these pathways with simple interventions can be effective. Glycine, an inexpensive and safe naturally occurring molecule, holds promise for mitigating chemotherapy-related cognitive decline during cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.